文献速递重症综合管理与镇静镇痛

死亡率作为危重症患者临床试验治疗效果的衡量指标

Mortality As a Measure of Treatment Effect in Clinical Trials Recruiting Critically Ill Patients.
PubMed 文献 · Crit Care Med · 2023-01-20
一句话结论在ICU随机试验中,不同治疗组间的死亡率差异可持续至招募后60-90天,且仅30.2%显示死亡率获益的干预被广泛采纳。

该研究检索1990-2018年OVID Medline,纳入343项RCT(228,784例成人患者),评估全因死亡率作为结局指标的时间进程、对治疗差异的反应性及对指南的影响。结果显示,180天内死亡的三分之一发生在第7天前,组间风险差持续增加至第60天(P=0.01)并可能至第90天(P=0.07),此后稳定;ICU出院死亡数近似28-30天(95%[IQR 86-106%]),出院死亡数近似60天(99%[IQR 94-104%])。43项显示死亡率获益的干预中仅13项(30.2%)被广泛采纳。结论提示选择时间窗和解读死亡率结局需考虑差异效应持续时间,且死亡率降低对实践影响有限。

要点

  • 不同治疗组间死亡率风险差持续增加至第60天(P=0.01)并可能至第90天(P=0.07),此后保持稳定。
  • 180天内所有死亡的三分之一发生在第7天前,提示早期死亡占比高但组间差异未早期固定。
  • ICU出院时死亡数近似28-30天死亡数(95%[IQR 86-106%]),出院时死亡数近似60天死亡数(99%[IQR 94-104%])。
  • 43项显示死亡率获益的干预中仅13项(30.2%)被广泛采纳进入临床实践。
  • 基于地点(ICU出院、出院)的死亡指标可近似基于时间的指标,用于美国以外的试验。

适用人群与场景

  • 纳入标准:随机≥100例患者、发表于五本高影响力综合医学期刊或八本重症医学期刊之一、报告至少两个不同时间点死亡率的RCT。
  • 排除标准:招募儿科或新生儿患者的试验、整群随机对照试验。
  • 研究人群为成人危重症患者,共343项RCT、228,784例成人患者。

研究设计与关键结果

  • 研究类型:文献检索与汇总分析,检索OVID Medline 1990-2018年发表的RCT;从2,592项可能合格的试验中纳入343项RCT(228,784例成人患者)。
  • 主要结果:180天内所有死亡的三分之一发生在第7天前;组间风险差持续增加至第60天(P=0.01)并可能至第90天(P=0.07),此后保持稳定。
  • 时间点替代:ICU出院时死亡数近似28-30天死亡数(95%[IQR 86-106%]);出院时死亡数近似60天死亡数(99%[IQR 94-104%])。
  • 实践影响:43项显示死亡率获益的干预中仅13项(30.2%)被广泛采纳进入临床实践。
  • 试验影响评估方法:通过结果是否被纳入临床实践指南来评估。

证据类型、等级与局限

  • 证据类型:对1990-2018年发表的RCT进行的汇总分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文结论提示:在急性疾病试验中选择时间窗和解读死亡率结局时,应考虑不同治疗效应可持续60至90天。
  • 原文结论提示:基于地点(ICU出院、出院)的死亡指标可近似基于时间的指标,用于美国以外开展的试验。
  • 原文结论提示:死亡率降低的记录对临床实践的影响有限(43项中仅13项被广泛采纳)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: All-cause mortality is a common measure of treatment effect in ICU-based randomized clinical trials (RCTs). We sought to understand the performance characteristics of a mortality endpoint by evaluating its temporal course, responsiveness to differential treatment effects, and impact when used as an outcome measure in trials of acute illness.

DATA SOURCES: We searched OVID Medline for RCTs published from 1990 to 2018.

STUDY SELECTION: We reviewed RCTs that had randomized greater than or equal to 100 patients, were published in one of five high-impact general medical or eight critical care journals, and reported mortality at two or more distinct time points. We excluded trials recruiting pediatric or neonatal patients and cluster RCTs.

DATA EXTRACTION: Mortality by randomization group was recorded from the article or estimated from survival curves. Trial impact was assessed by inclusion of results in clinical practice guidelines.

DATA SYNTHESIS: From 2,592 potentially eligible trials, we included 343 RCTs (228,784 adult patients). While one third of all deaths by 180 days had occurred by day 7, the risk difference between study arms continued to increase until day 60 (p = 0.01) and possibly day 90 (p = 0.07) and remained stable thereafter. The number of deaths at ICU discharge approximated those at 28-30 days (95% [interquartile range [IQR], 86-106%]), and deaths at hospital discharge approximated those at 60 days (99% [IQR, 94-104%]). Only 13 of 43 interventions (30.2%) showing a mortality benefit have been adopted into widespread clinical practice.

CONCLUSIONS: Our findings provide a conceptual framework for choosing a time horizon and interpreting mortality outcome in trials of acute illness. Differential mortality effects persist for 60 to 90 days following recruitment. Location-based measures approximate time-based measures for trials conducted outside the United States. The documentation of a mortality reduction has had a modest impact on practice.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Friedrich JO, Harhay MO, Angus DC, et al. Mortality As a Measure of Treatment Effect in Clinical Trials Recruiting Critically Ill Patients. Crit Care Med. 2023. PMID: 36661450. doi:10.1097/CCM.0000000000005721

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。